SLC44A1抗体

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human prostate cancer tissue using P05312(SLC44A1 Antibody) at dilution 1/20. (Original magnification: ×200)    

  
  

The SLC44A1 antibody targets the solute carrier family 44 member 1 (SLC44A1), a transmembrane protein implicated in choline transport and cellular signaling. SLC44A1. also known as CTL1 or CHTL1. belongs to the SLC44 family, which is evolutionarily distinct from other choline transporters. It is widely expressed in tissues, including the nervous system, blood cells, and epithelial cells, where it regulates choline uptake for phospholipid synthesis and acetylcholine production. Research highlights its role in supporting myelination in Schwann cells and modulating immune responses, as SLC44A1 is associated with neutrophil-specific antigens (HNA-3) implicated in transfusion-related acute lung injury (TRALI).

SLC44A1 antibodies have gained attention in autoimmune and cancer research. Autoantibodies against SLC44A1 are detected in conditions like rheumatoid arthritis and primary biliary cholangitis, suggesting a link to autoimmunity. In cancer, SLC44A1 overexpression is observed in prostate, colorectal, and glioblastoma tumors, correlating with disease progression and poor prognosis. Antibodies against SLC44A1 are utilized in research to study its localization, expression patterns, and functional roles through techniques like Western blotting, immunohistochemistry, and flow cytometry. However, discrepancies in reported expression levels across studies underscore the need for antibody validation, as splice variants or post-translational modifications may affect detection. Ongoing studies aim to clarify its pathophysiological mechanisms and therapeutic potential.